These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 5309476

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT.
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [Abstract] [Full Text] [Related]

  • 3. The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.
    Hilleman MR.
    Bull World Health Organ; 1969 Oct; 41(3):623-8. PubMed ID: 4985377
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA.
    Vaccine; 2007 May 22; 25(21):4283-90. PubMed ID: 17403562
    [Abstract] [Full Text] [Related]

  • 6. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2006 Jul 22; 78(7):954-63. PubMed ID: 16721854
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004.
    Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, Averhoff F, Chaves SS, Gargiullo P, Bridges CB.
    Vaccine; 2007 Jan 02; 25(1):154-60. PubMed ID: 17064823
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.
    Li S, Perdue ML, Patzer E.
    Dev Biol (Basel); 2002 Jan 02; 110():135-41. PubMed ID: 12477316
    [Abstract] [Full Text] [Related]

  • 15. [Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
    Baldo V, Menegon T, Buoro S, Scalici C, Vesco A, Perale S, Boato W, Carletti M, Bonello C, Dalla Costa D, Trivello R.
    Ann Ig; 1999 Jan 02; 11(5):369-74. PubMed ID: 10596424
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 18. A universal epitope-based influenza vaccine and its efficacy against H5N1.
    Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T.
    Vaccine; 2009 Mar 26; 27(15):2099-107. PubMed ID: 19356612
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.